Hyaluronic acid, skinboosters and biostimulators: a complete guide to making an informed choice (2026)

1 Three families, three philosophies

It is common to hear about a "hyaluronic acid injection" as if it were a single, uniform procedure. Clinical reality is far more nuanced. A dense volumising filler used to restore the cheekbones has almost nothing in common with a liquid intradermal skinbooster like Skinvive, which is itself fundamentally different from a biostimulator like Sculptra. These are three families of products, three distinct mechanisms of action, three different therapeutic objectives.

The emergence in 2024-2025 of hybrid products such as Skinvive by Juvederm and HArmonyCa has further complicated the landscape: these innovations blur the boundaries between existing categories and address needs that neither fillers alone nor classic biostimulators covered perfectly.

The starting point of any injection decision must be a precise diagnosis: is there a lack of volume? A loss of skin quality and hydration? Deep structural laxity? The answer to this question determines the family of product — and the competent practitioner always starts there, before discussing brand or technique.

2 Hyaluronic acid: biology and mechanisms

Hyaluronic acid (HA) is a molecule naturally present in the skin, joints and eyes. In the dermis, it plays a central role in tissue hydration, cellular turgor and maintenance of the collagen network. With age, its concentration decreases significantly — it is estimated that around 50% of cutaneous HA is lost between the ages of 25 and 50 — contributing directly to the loss of firmness, radiance and skin density.

One common confusion deserves immediate clarification: applying a cream containing hyaluronic acid does not produce the same effects as an injection. The HA molecule is too large to cross the skin barrier and reach the deep dermis. Its topical action remains superficial — hydrating the stratum corneum, creating a film-forming effect — without reaching the compartments where tissue ageing actually takes place.

Medical injectable HA is produced by bacterial fermentation and undergoes cross-linking processes — chemical bonds (BDDE) that stabilise the molecule, slow its enzymatic degradation and modify its rheological properties. It is the nature and intensity of this cross-linking that fundamentally distinguishes the three families: a filler is highly cross-linked to create stable volume, a skinbooster is little or not cross-linked in order to diffuse freely through the tissues, and an HA biostimulator (as in HArmonyCa) presents intermediate cross-linking.

The decisive advantage of injectable HA remains its reversibility: hyaluronidase, an enzyme administered by injection, can dissolve HA products within a few hours. This advantage should not, however, minimise the risks — particularly vascular ones — which exist independently of the product's reversibility.

3 HA fillers: adding volume and reshaping

The hyaluronic acid filler is the best-known and oldest form of aesthetic injectable. Its principle is mechanical and immediate: a dense, highly cross-linked gel is deposited in the deep planes (subcutaneous, supraperiosteal) to create or restore volume. The effect is visible from the session itself — this is its main differentiating feature.

The indications are numerous and cover most of non-surgical facial remodelling: restoration of lost volumes (cheekbones, temples, chin, jawline), correction of deep nasolabial folds, lip augmentation, correction of the nasal profile through medical rhinoplasty. Each area requires an appropriate product: a light, low-cohesivity HA for the lips or tear troughs, an HA of intermediate density for folds, a dense and highly cohesive HA for the cheekbones or chin where structural support is essential.

Durability varies according to the area and individual metabolism: from 6 to 8 months for the lips (highly vascularised, high mobility), to 12-18 months for the cheekbones and chin, and sometimes beyond 24 months in areas of deep injection in contact with bone. One important clinical point: accumulation of product from one session to another, without prior dissolution of residues, can lead to unnatural results. A rigorous practitioner assesses the residual capital before each additional injection.

4 Skinboosters: Profhilo, Skinvive and others

The skinbooster family is based on a logic that is radically different from the filler: the goal is not to create volume, but to inject into the superficial dermis an HA that is little or not cross-linked, which will diffuse through the tissues, deeply hydrate the dermis and stimulate fibroblast activity to restart endogenous production of collagen and elastin. The result is not added volume, but an improvement in the intrinsic quality of the skin: texture, radiance, hydration, slight firmness.

Profhilo (IBSA)

Profhilo represents a major step forward in the skinbooster family. Its NAHYCO formulation — highly concentrated HA at 64 mg/2 ml, non-cross-linked, combining high and low molecular weight HA — gives it broad tissue diffusion capacity and simultaneously stimulates four types of collagen and elastin. The BAP (Basic Aesthetic Points) injection protocol, using 5 points per hemiface, takes advantage of this diffusion to cover large surfaces from limited injection points. Results concern skin density, radiance and a slight improvement in firmness. Durability is 6 to 9 months with an initial protocol of two sessions spaced one month apart.

Skinvive by Juvederm (Allergan/AbbVie)

Skinvive, marketed in Europe under the name Juvederm Volite, is the first injectable HA approved by the FDA (May 2023) specifically to improve skin texture and hydration without adding volume. Its Vycross technology — combining low and high molecular weight HA with light BDDE cross-linking (12 mg/ml) with lidocaine — provides diffusion in precise micro-deposits rather than broad diffusion. This precision opens up areas inaccessible to Profhilo: eye contour, forehead, neck. The FDA pivotal study (131 patients) documented 96% smoother skin at one month and 91% satisfaction maintained at six months. An extension to neck wrinkles was accepted by the FDA in June 2025, with 80% improvement at one month.

The question often asked — Profhilo or Skinvive? — should not set these two products against each other: they are complementary, not interchangeable. Profhilo restructures globally through high-concentration biostimulation and broad diffusion; Skinvive hydrates and improves texture with greater precision in targeted areas. The choice depends on the objective and the topography to be treated.

Comparative table of skinboosters

5 Biostimulators: regenerating the deep structure

Biostimulators represent a paradigm shift compared to the two previous families. They do not directly add volume and do not merely hydrate the dermis: they induce a biological response that leads the body to produce its own collagen, elastin and endogenous HA. The effect is progressive — the full result appears between three and six months after the injections — and its durability exceeds that of classic HA fillers.

HArmonyCa (Allergan/AbbVie) — the hybrid biostimulator

HArmonyCa is the first injectable product combining, in a single syringe, a volumising HA, calcium hydroxyapatite (CaHA) biostimulator microspheres and lidocaine. Its dual action is its clinical signature: an immediate lifting effect from the injection — thanks to HA that hydrates in the tissues — followed by progressive neocollagenesis over three to six months induced by the CaHA. The HA disappears after 9 to 12 months, but the collagen framework induced by the CaHA endures, giving HArmonyCa an overall durability estimated at 18 months. It sits naturally between the HA filler (for volume) and Sculptra (for deep biostimulation) — an ideal middle path for patients seeking immediate result and durability.

Sculptra (PLLA)

Sculptra, based on poly-L-lactic acid (PLLA), acts through controlled micro-inflammation around its particles, progressively stimulating fibroblasts to produce type I collagen. Volume restoration and tissue densification occur simultaneously. Two to three sessions spaced four to six weeks apart are generally necessary. The full result is appreciated at three to six months, with a durability of 18 to 24 months and beyond. Appropriate dilution and post-injection massage are essential technical precautions to prevent late nodules.

Radiesse (CaHA) and Ellansé (PCL)

Radiesse, based on calcium hydroxyapatite, offers a dual immediate (volumising) and delayed (biostimulating) action. In a hyperdiluted technique — Radiesse heavily diluted in saline or lidocaine solution — it is used as a pure biostimulator on the neck, décolleté, hands and body, without volumising effect. Ellansé, based on polycaprolactone (PCL), stands out for its four ranges (S, M, L, XL) with durations of action from one to four years, allowing durability to be tailored to the therapeutic project and the patient's profile.

Comparative table of biostimulators

6 How to choose: filler, skinbooster or biostimulator?

The question of choice between these three families should never start from the product, but from the diagnosis. Three structuring questions help guide the decision: is there a lack of volume? A loss of skin quality (dryness, dullness, uneven texture)? Structural laxity and a loss of deep density? The answer to each of these questions points to a distinct family.

In a global protocol, a logical order emerges: biostimulator as a foundation (restructuring the deep matrix), skinbooster for skin quality, filler for targeted correction. This sequence produces the best results at each anatomical level, without over-treatment.

Combinations are possible, with precautions: Skinvive and HA filler can be administered on the same day in distinct areas. HArmonyCa and botulinum toxin are a frequent and coherent combination. Profhilo and HA filler complement each other naturally. On the other hand, it is recommended to space Sculptra and fillers at least four to six weeks apart to avoid interference in the tissue inflammatory response.

The best injection is the one that meets the right objective with the right product in the right area. The practitioner's competence lies in their ability to diagnose before injecting — and to refuse systematic injection where it is not the appropriate response.

Comparative table of the three families

7 Risks and safety

The most serious risk in all injectable aesthetic medicine is vascular occlusion. It concerns all injectable products — HA, PLLA, CaHA, PCL — whenever the injection is performed in a vascularised area. Occlusion occurs when the product compresses or obstructs a blood vessel, which can lead to skin necrosis, or — in high-risk areas such as the nose, glabella or lips — to blindness through vascular anastomosis with the ophthalmic artery. Immediate warning signs — skin blanching, intense pain, blurred vision — should prompt emergency intervention with hyaluronidase injection for HA products. For non-HA biostimulators, no antidote exists, which reinforces the requirement for flawless technique.

The irreversibility of non-HA biostimulators is information that every patient must receive before signing consent. Sculptra (PLLA), Radiesse (pure CaHA) and Ellansé (PCL) do not dissolve with hyaluronidase. HArmonyCa is a partial exception — its HA component is dissolvable, but the CaHA microspheres are not. In practice, this partial irreversibility of HArmonyCa is a safety advantage over pure biostimulators.

Among the more common and generally transient side effects: bruising at the injection site, post-session swelling, minor asymmetry, Tyndall effect (bluish colouration visible under the skin when HA is injected too superficially). Late nodules, possible with Sculptra and Radiesse, are technique-dependent and preventable through adequate dilution and rigorous post-injection massage.

8 Choosing your practitioner in Switzerland

In Switzerland, injections of hyaluronic acid, biostimulators and skinboosters are medical acts that can legally only be performed by authorised physicians. Swissmedic regulation governs injectable medical products, and the cantons define the conditions of practice. This regulation protects patients — and it is legitimate to verify the practitioner's qualifications before any consultation.

A serious practitioner always begins with a complete medical consultation: anamnesis, facial analysis, discussion of objectives and expectations, explanation of the chosen product (name, composition, volume), description of the protocol and its risks. Traceability is a fundamental right: every patient must be able to know exactly which product has been injected, in which area, in what quantity and by whom. This information must be recorded in the medical file.

The warning signs to watch for are clear: no prior medical consultation, unnamed products or brands not communicated, abnormally low prices, injections performed by non-medical staff. Quality aesthetic medicine is not negotiated on price — it is chosen based on competence, traceability and transparency.

9 Conclusion

The landscape of aesthetic injectables in 2026 is richer and more nuanced than ever. HA fillers remain the reference for immediate volume correction. Skinboosters — Profhilo for global restructuring, Skinvive for targeted precision — meet the growing need for improving skin quality without adding volume. Biostimulators — HArmonyCa for the immediate and lasting hybrid effect, Sculptra for deep biostimulation, Radiesse for the body, Ellansé for adjustable durability — establish themselves as the structural foundation of any comprehensive injectable protocol.

2024-2025 marks a turning point: Skinvive and HArmonyCa have opened therapeutic paths between existing categories, making possible what neither fillers alone nor classic biostimulators covered perfectly. These innovations confirm an underlying trend: towards more natural, more lasting results, based on the patient's own biology rather than simple volume replacement.

The best decision is always an informed decision — made after a precise diagnosis, an honest explanation of mechanisms, durability and risks, and a choice of practitioner based on documented competence rather than on the attractiveness of the price.